Creative Planning
SLNO

Creative Planning’s Soleno Therapeutics SLNO Stock Holding History

Creative Planning’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,789
Closed -$222K – 4190
2025
Q4 		$222K Sell
4,789
-96
-2% -$5.26K ﹤0.01% 3471
2025
Q3 		$330K Buy
4,885
+855
+21% +$63.4K ﹤0.01% 3068
2025
Q2 		$338K Buy
+4,030
New +$302K ﹤0.01% 2792
2017
Q3 		– Sell
-17
Closed -$1K – 3424
2017
Q2 		$1K Buy
+17
New +$788 ﹤0.01% 4488

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Creative Planning's SLNO Position: Q1 2026 in Review

Creative Planning sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 4,789 shares — an estimated $222K sold.

Creative Planning first reported a position in SLNO in Q2 2017 and held it in 4 quarters. The position peaked at $338K in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Creative Planning reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Creative Planning sold 4,789 Soleno Therapeutics shares in Q1 2026, an estimated $222K.
  • Creative Planning first reported a position in Soleno Therapeutics in Q2 2017 and held it in 4 quarters.
  • Creative Planning's Soleno Therapeutics position peaked at $338K in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.